Einzeltreffer — DigiBib

Background: Pancreatic ductal adenocarcinoma (PDAC), one of the most lethal malignancies, is increasing in incidence. However, the stromal reaction pathophysiology and its role in PDAC development remain unknown. We, therefore, investigated the potential role of histological chronic pancreatitis findings and chronic inflammation on surgical PDAC specimens and disease-specific survival (DSS).

Methods: Between 2000 and 2016, we retrospectively enrolled 236 PDAC patients treated with curative-intent pancreatic surgery at Helsinki University Hospital. All pancreatic transection margin slides were re-reviewed and histological findings were evaluated applying international guidelines.

Results: DSS among patients with no fibrosis, acinar atrophy or chronic inflammation identified on pathology slides was significantly better than DSS among patients with fibrosis, acinar atrophy and chronic inflammation [median survival: 41.8 months, 95% confidence interval (CI) 26.0-57.6 vs. 20.6 months, 95% CI 10.3-30.9; log-rank test p = 0.001]. Multivariate analysis revealed that Ca 19-9 > 37 kU/l [hazard ratio (HR) 1.48, 95% CI 1.02-2.16], lymph node metastases N1-2 (HR 1.71, 95% CI 1.16-2.52), tumor size > 30 mm (HR 1.47, 95% CI 1.04-2.08), the combined effect of fibrosis and acinar atrophy (HR 1.91, 95% CI 1.27-2.88) and the combined effect of fibrosis, acinar atrophy and chronic inflammation (HR 1.63, 95% CI 1.03-2.58) independently served as unfavorable prognostic factors for DSS. However, we observed no significant associations between tumor size (> 30 mm) and the degree of perilobular fibrosis (p = 0.655), intralobular fibrosis (p = 0.587), acinar atrophy (p = 0.584) or chronic inflammation (p = 0.453).

Conclusions: Our results indicate that the pancreatic stroma is associated with PDAC patients' DSS. Additionally, the more severe the fibrosis, acinar atrophy and chronic inflammation, the worse the impact on DSS, thereby warranting further studies investigating stroma-targeted therapies.

Titel:	Pancreatic fibrosis, acinar atrophy and chronic inflammation in surgical specimens associated with survival in patients with resectable pancreatic ductal adenocarcinoma.
Autor/in / Beteiligte Person:	Korpela, T ; Ristimäki, A ; Udd, M ; Vuorela, T ; Mustonen, H ; Haglund, C ; Kylänpää, L ; Seppänen, H
Link:	Zum Volltext
Zeitschrift:	BMC cancer, Jg. 22 (2022-01-03), Heft 1, S. 23
Veröffentlichung:	London : BioMed Central, [2001-, 2022
Medientyp:	academicJournal
ISSN:	1471-2407 (electronic)
DOI:	10.1186/s12885-021-09080-0
Schlagwort:	Adult Aged Aged, 80 and over Atrophy Biomarkers, Tumor analysis Chronic Disease Disease-Free Survival Female Fibrosis Humans Inflammation Male Middle Aged Pancreatectomy mortality Pancreatitis complications Prognosis Proportional Hazards Models Retrospective Studies Risk Factors Survival Rate Acinar Cells pathology Carcinoma, Pancreatic Ductal mortality Carcinoma, Pancreatic Ductal pathology Pancreas pathology Pancreatic Neoplasms mortality Pancreatic Neoplasms pathology
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article Language: English [BMC Cancer] 2022 Jan 03; Vol. 22 (1), pp. 23. <i>Date of Electronic Publication: </i>2022 Jan 03. MeSH Terms: Acinar Cells / pathology ; Carcinoma, Pancreatic Ductal / mortality ; Carcinoma, Pancreatic Ductal / pathology ; Pancreas / pathology ; Pancreatic Neoplasms / mortality ; Pancreatic Neoplasms / pathology ; Adult ; Aged ; Aged, 80 and over ; Atrophy ; Biomarkers, Tumor / analysis ; Chronic Disease ; Disease-Free Survival ; Female ; Fibrosis ; Humans ; Inflammation ; Male ; Middle Aged ; Pancreatectomy / mortality ; Pancreatitis / complications ; Prognosis ; Proportional Hazards Models ; Retrospective Studies ; Risk Factors ; Survival Rate References: PLoS One. 2020 Jul 13;15(7):e0234568. (PMID: 32658932) ; Pancreatology. 2020 Jul;20(5):910-918. (PMID: 32624419) ; Curr Opin Pharmacol. 2009 Aug;9(4):411-8. (PMID: 19589727) ; Br J Surg. 2015 Nov;102(12):1459-72. (PMID: 26350029) ; Am J Gastroenterol. 2017 Sep;112(9):1366-1372. (PMID: 28762376) ; Gut. 2018 Jan;67(1):146-156. (PMID: 27646934) ; Int J Surg. 2013;11(10):1067-72. (PMID: 24161419) ; PLoS One. 2016 Sep 15;11(9):e0163064. (PMID: 27632196) ; Br J Surg. 2003 Feb;90(2):215-9. (PMID: 12555298) ; Cancer Epidemiol. 2020 Feb;64:101647. (PMID: 31811984) ; N Engl J Med. 2018 Dec 20;379(25):2395-2406. (PMID: 30575490) ; Pancreatology. 2020 Mar;20(2):254-264. (PMID: 31866391) ; Int J Clin Oncol. 2021 Oct;26(10):1922-1928. (PMID: 34110531) ; JAMA. 2013 Oct 9;310(14):1473-81. (PMID: 24104372) ; Int J Cancer. 2015 May 1;136(9):2216-27. (PMID: 25273947) ; Am J Gastroenterol. 2007 Dec;102(12):2696-707. (PMID: 17764494) ; Pancreas. 1991 May;6(3):266-74. (PMID: 1862065) ; JAMA. 2010 Sep 8;304(10):1073-81. (PMID: 20823433) ; BMC Cancer. 2019 Aug 29;19(1):858. (PMID: 31464604) ; CA Cancer J Clin. 2018 Jan;68(1):7-30. (PMID: 29313949) ; Am J Pathol. 2010 Nov;177(5):2585-96. (PMID: 20934972) ; Biochem Biophys Res Commun. 2009 May 8;382(3):561-5. (PMID: 19292977) ; J Clin Oncol. 2020 Jun 1;38(16):1763-1773. (PMID: 32105518) ; Arch Pathol Lab Med. 2009 Mar;133(3):382-7. (PMID: 19260744) ; Int J Cancer. 2020 Sep 1;147(5):1450-1460. (PMID: 32162688) ; Cancer Cell. 2007 Mar;11(3):291-302. (PMID: 17349585) ; Eur J Med Res. 2020 Oct 7;25(1):46. (PMID: 33028394) ; Ann Oncol. 2012 Nov;23(11):2964-2970. (PMID: 22767586) ; Pancreatology. 2010;10(2-3):186-93. (PMID: 20484957) ; Nature. 2008 Jul 24;454(7203):436-44. (PMID: 18650914) ; N Engl J Med. 1993 May 20;328(20):1433-7. (PMID: 8479461) ; Ann Oncol. 2014 Oct;25(10):2065-2072. (PMID: 25057164) ; Neoplasia. 2014 Jun;16(6):463-70. (PMID: 24953430) ; Dig Liver Dis. 2017 Nov;49(11):1249-1256. (PMID: 28756974) ; HPB (Oxford). 2015 Apr;17(4):292-8. (PMID: 25250696) ; Br J Cancer. 2014 Jan 7;110(1):183-8. (PMID: 24201751) ; Cell. 2019 Jun 27;178(1):160-175.e27. (PMID: 31155233) ; Pancreas. 2018 Nov-Dec;47(10):1262-1266. (PMID: 30286010) ; Pancreatology. 2020 Jun;20(4):586-593. (PMID: 32414657) ; Ann Oncol. 2012 Apr;23(4):843-52. (PMID: 21890910) ; Front Oncol. 2020 Aug 21;10:1472. (PMID: 32974173) Contributed Indexing: Keywords: Chronic pancreatitis; Pancreatic cancer; Stroma; Tumor–stroma interactions Substance Nomenclature: 0 (Biomarkers, Tumor) Entry Date(s): Date Created: 20220104 Date Completed: 20220303 Latest Revision: 20220303 Update Code: 20240513 PubMed Central ID: PMC8721973

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

Pancreatic fibrosis, acinar atrophy and chronic inflammation in surgical specimens associated with survival in patients with resectable pancreatic ductal adenocarcinoma.